MAPT and Alzheimer disease: Furthermore, tau is pivotal in AD onset; therefore, pharmaceuticals that specifically target tau pathology in AD are still in the developmental stage and require further testing.[18] As an alternative approach, there is interest in natural products that target tau hyperphosphorylation and its aggregation.